Aprea Therapeutics Inc Stock price
Is Aprea Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Aprea Therapeutics Inc Stock Analysis
Analyst Opinions
10 Analysts have issued a Aprea Therapeutics Inc forecast:
Analyst Opinions
10 Analysts have issued a Aprea Therapeutics Inc forecast:
Don't miss a Thing! We will send you all news about Aprea Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aprea Therapeutics Inc Stock News
Company Profile
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Dr. Gilad |
| Employees | 8 |
| Founded | 2002 |
| Website | www.aprea.com |


